Ovarian cancer

Annual Review of Pathology: Mechanisms of Disease

Volumn 4, Issue , 2009, Pages 287-313

  Cho, Kathleen R ^a   Shih, Ie Ming ^b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

Classification; Endometrioid; Genetics; Mouse models; Serous

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; DNA; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; NOTCH3 RECEPTOR; QUERCETIN; RAPAMYCIN;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER MORPHOLOGY; CANCER MORTALITY; CANCER SCREENING; CELL CYCLE ARREST; CELL CYCLE REGULATION; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CLEAR CELL CARCINOMA; CLINICAL FEATURE; CLINICAL TRIAL; COMPARATIVE GENOMIC HYBRIDIZATION; CYTOREDUCTIVE SURGERY; DIAGNOSTIC TEST; DISEASE FREE INTERVAL; DISEASE SEVERITY; DRUG BIOAVAILABILITY; DRUG EFFICACY; ENDOMETRIOID CARCINOMA; ENDOMETRIOSIS; EPITHELIUM TUMOR; GENE AMPLIFICATION; GENE EXPRESSION; GENE NUMBER; GENE OVEREXPRESSION; GENETIC IDENTIFICATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; KARYOTYPING; MOLECULAR BIOLOGY; MOLECULAR GENETICS; MUCINOUS CARCINOMA; MUTATION; MUTATIONAL ANALYSIS; NONHUMAN; OUTCOME ASSESSMENT; OVARY CANCER; OVARY CARCINOMA; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION; TREATMENT DURATION; ANIMAL; CLASSIFICATION; DISEASE MODEL; FEMALE; GENE EXPRESSION REGULATION; GENETICS; GENOTYPE; MOUSE; NOMENCLATURE; OVARY TUMOR; PATHOLOGY; PATIENT SELECTION; PHENOTYPE; TREATMENT OUTCOME;

ANIMALS; CELL DIFFERENTIATION; DISEASE MODELS, ANIMAL; EARLY DETECTION OF CANCER; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOTYPE; HUMANS; MICE; OVARIAN NEOPLASMS; PATIENT SELECTION; PHENOTYPE; TERMINOLOGY AS TOPIC; TREATMENT OUTCOME;

EID: 66149083645     PISSN: 15534006     EISSN: 15534014     Source Type: Book Series    
DOI: 10.1146/annurev.pathol.4.110807.092246     Document Type: Review

References (144)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. 2007. Cancer statistics, 2007. CA Cancer J. Clin. 57:43-66
2. Feeley KM, Wells M. 2001. Precursor lesions of ovarian epithelial malignancy. Histopathology 38:87-95
3. Bell DA. 2005. Origins and molecular pathology of ovarian cancer. Mod. Pathol. 18(Suppl. 2):S19-32
4. Dubeau L. 1999. The cell of origin of ovarian epithelial tumors and the ovarian surface epithelium dogma: Does the emperor have no clothes? Gynecol. Oncol. 72:437-442 (Pubitemid 29118208)
5. Kurman RJ. 2002. Blaustein's Pathology of the Female Genital Tract. New York: Springer-Verlag. 5th ed.
6. Kindelberger DW, Lee Y, Miron A, Hirsch MS, Feltmate C, et al. 2007. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am. J. Surg. Pathol. 31:161-169 (Pubitemid 46175016)
7. Crum CP, Drapkin R, Kindelberger D, Medeiros F, Miron A, Lee Y. 2007. Lessons from BRCA: the tubal fimbria emerges as an origin for pelvic serous cancer. Clin. Med. Res. 5:35-44 (Pubitemid 350218778)
8. Silverberg SG. 2000. Histopathologic grading of ovarian carcinoma: a review and proposal. Int. J. Gynecol. Pathol. 19:7-15 (Pubitemid 30010638)
9. Shimizu Y, Kamoi S, Amada S, Akiyama F, Silverberg SG. 1998. Toward the development of a universal grading system for ovarian epithelial carcinoma: testing of a proposed system in a series of 461 patients with uniform treatment and follow-up. Cancer 82:893-901 (Pubitemid 28104169)
10. Malpica A, Deavers MT, Lu K, Bodurka DC, Atkinson EN, et al. 2004. Grading ovarian serous carcinoma using a two-tier system. Am. J. Surg. Pathol. 28:496-504 (Pubitemid 38436523)
11. Seidman JD, Horkayne-Szakaly I, Cosin JA, RyuHS, Haiba M, et al. 2006. Testing of two binary grading systems for FIGO stage III serous carcinoma of the ovary and peritoneum. Gynecol. Oncol. 103:703-708 (Pubitemid 44602191)
12. Di Cristofano A, Ellenson LH. 2007. Endometrial carcinoma. Annu. Rev. Pathol. Mech. Dis. 2:57-85
13. Seidman JD, Horkayne-Szakaly I, Haiba M, Boice CR, Kurman RJ, Ronnett BM. 2004. The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin. Int. J. Gynecol. Pathol. 23:41-44 (Pubitemid 38018236)
14. Tammela J, Geisler JP, Eskew PN Jr, Geisler HE. 1998. Clear cell carcinoma of the ovary: poor prognosis compared to serous carcinoma. Eur. J. Gynaecol. Oncol. 19:438-440 (Pubitemid 28479390)
15. Sugiyama T, Kamura T, Kigawa J, Terakawa N, Kikuchi Y, et al. 2000. Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer 88:2584-2589 (Pubitemid 30331967)
16. Hart WR. 2005. Mucinous tumors of the ovary: a review. Int. J. Gynecol. Pathol. 24:4-25
17. Wood LD, Parsons DW, Jones S, Lin J, Sjoblom T, et al. 2007. The genomic landscapes of human breast and colorectal cancers. Science 318:1108-1113 (Pubitemid 350134889)
18. Wang Z, Shen D, Parsons DW, Bardelli A, Sager J, et al. 2004. Mutational analysis of the tyrosine phosphatome in colorectal cancers. Science 304:1164-1166 (Pubitemid 38661854)
19. Wang TL, Maierhofer C, Speicher MR, Lengauer C, Vogelstein B, et al. 2002. Digital karyotyping. Proc. Natl. Acad. Sci. USA 99:16156-16161
20. Leary RJ, Cummins J, Wang TL, Velculescu VE. 2007. Digital karyotyping. Nat. Protoc. 2:1973-1986
21. Schwartz DR, Kardia SL, Shedden KA, Kuick R, Michailidis G, et al. 2002. Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Cancer Res. 62:4722-4729 (Pubitemid 34898601)
22. Schaner ME, Ross DT, Ciaravino G, Sorlie T, Troyanskaya O, et al. 2003. Gene expression patterns in ovarian carcinomas. Mol. Biol. Cell 14:4376-4386 (Pubitemid 37444641)
23. Marquez RT, Baggerly KA, Patterson AP, Liu J, Broaddus R, et al. 2005. Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon. Clin. Cancer Res. 11:6116-6126 (Pubitemid 41262937)
24. Wu R, Hendrix-Lucas N, Kuick R, Zhai Y, Schwartz DR, et al. 2007. Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/β-catenin and PI3K/PTEN signaling pathways. Cancer Cell 11:321-333 (Pubitemid 46518315)
25. Vang R, Shih IeM, Salani R, Sugar E, Ayhan A, Kurman RJ. 2008. Subdividing ovarian and peritoneal serous carcinoma into moderately and poorly differentiated does not have biologic validity based on molecular genetic and in vitro drug resistance data. Am. J. Surg. Pathol. In press
26. Singer G, Stohr R, Cope L, Dehari R, Hartmann A, et al. 2005. Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Am. J. Surg. Pathol. 29:218-224 (Pubitemid 40170640)
27. Willner J, Wurz K, Allison KH, Galic V, Garcia RL, et al. 2007. Alternate molecular genetic pathways in ovarian carcinomas of common histological types. Hum. Pathol. 38:607-613 (Pubitemid 46399888)
28. Singer G, Oldt R 3rd, Cohen Y, Wang BG, Sidransky D, et al. 2003. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J. Natl. Cancer Inst. 95:484-486
29. Merajver SD, Pham TM, Caduff RF, Chen M, Poy EL, et al. 1995. Somatic mutations in the BRCA1 gene in sporadic ovarian tumours. Nat. Genet. 9:439-443
30. Nakayama K, Nakayama N, Kurman RJ, Cope L, Pohl G, et al. 2006. Sequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms. Cancer Biol. Ther. 5:779-785 (Pubitemid 44775134)
31. Afify AM, Werness BA, Mark HF. 1999. HER-2/neu oncogene amplification in stage I and stage III ovarian papillary serous carcinoma. Exp. Mol. Pathol. 66:163-169
32. Nakayama K, Nakayama N, Jinawath N, Salani R, Kurman RJ, et al. 2007. Amplicon profiles in ovarian serous carcinomas. Int. J. Cancer 120:2613-2617 (Pubitemid 46651282)
33. Kupryjanczyk J, Thor AD, Beauchamp R, Merritt V, Edgerton SM, et al. 1993. p53 gene mutations and protein accumulation in human ovarian cancer. Proc. Natl. Acad. Sci. USA 90:4961-4965 (Pubitemid 23182955)
34. Wen WH, Reles A, Runnebaum IB, Sullivan-Halley J, Bernstein L, et al. 1999. p53 mutations and expression in ovarian cancers: correlation with overall survival. Int. J. Gynecol. Pathol. 18:29-41 (Pubitemid 29028842)
35. Chan WY, Cheung KK, Schorge JO, Huang LW, Welch WR, et al. 2000. Bcl-2 and p53 protein expression, apoptosis, and p53 mutation in human epithelial ovarian cancers. Am. J. Pathol. 156:409-417 (Pubitemid 30643795)
36. Salani R, Kurman RJ, Giuntoli R 2nd, Gardner G, Bristow R, et al. 2008. Assessment of TP53 mutation using purified tissue samples of ovarian serous carcinomas reveals a higher mutation rate than previously reported and does not correlate with drug resistance. Int. J. Gynecol. Cancer 18:487-491
37. Leitao MM, Soslow RA, Baergen RN, Olvera N, Arroyo C, Boyd J. 2004. Mutation and expression of the TP53 gene in early stage epithelial ovarian carcinoma. Gynecol. Oncol. 93:301-306 (Pubitemid 38507593)
38. Vogelstein B, Kinzler KW. 2004. Cancer genes and the pathways they control. Nat. Med. 10:789-799 (Pubitemid 39070849)
39. Mok SC, Bell DA, Knapp RC, Fishbaugh PM, Welch WR, et al. 1993. Mutation of K-ras protooncogene in human ovarian epithelial tumors of borderline malignancy. Cancer Res. 53:1489-1492 (Pubitemid 23113216)
40. Sieben NL, Macropoulos P, Roemen GM, Kolkman-Uljee SM, Jan Fleuren G, et al. 2004. In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours. J. Pathol. 202:336-340 (Pubitemid 38325243)
41. Mayr D, Hirschmann A, Lohrs U, Diebold J. 2006. KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants. Gynecol. Oncol. 103:883-887 (Pubitemid 44821309)
42. Ueda M, Toji E, Noda S. 2007. Germ line and somatic mutations of BRAF V599E in ovarian carcinoma. Int. J. Gynecol. Cancer 17:794-797 (Pubitemid 47063319)
43. Wang SE, Narasanna A, Perez-Torres M, Xiang B, Wu FY, et al. 2006. HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Cancer Cell 10:25-38
44. Cheng EJ, Kurman RJ, Wang M, Oldt R, Wang BG, et al. 2004. Molecular genetic analysis of ovarian serous cystadenomas. Lab. Investig. 84:778-784 (Pubitemid 38715477)
45. Ho CL, Kurman RJ, Dehari R, Wang TL, Shih IeM. 2004. Mutations of BRAF and KRAS precede the development of ovarian serous borderline tumors. Cancer Res. 64:6915-6918 (Pubitemid 39330999)
46. Hsu CY, Bristow R, Cha MS, Wang BG, Ho CL, et al. 2004. Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas. Clin. Cancer Res. 10:6432-6436 (Pubitemid 39346537)
47. Pohl G, Ho CL, Kurman RJ, Bristow R, Wang TL, Shih IeM. 2005. Inactivation of the mitogen-activated protein kinase pathway as a potential target-based therapy in ovarian serous tumors with KRAS or BRAF mutations. Cancer Res. 65:1994-2000 (Pubitemid 40478629)
48. Allen LF, Sebolt-Leopold J, Meyer MB. 2003. CI-1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK). Semin. Oncol. 30:105-116 (Pubitemid 37433401)
49. Worsley SD, Ponder BA, Davies BR. 1997. Overexpression of cyclin D1 in epithelial ovarian cancers. Gynecol. Oncol. 64:189-195 (Pubitemid 27097565)
50. Sui L, Tokuda M, Ohno M, Hatase O, Hando T. 1999. The concurrent expression of p27(kip1) and cyclin D1 in epithelial ovarian tumors. Gynecol. Oncol. 73:202-209 (Pubitemid 29215732)
51. Gilks CB. 2004. Subclassification of ovarian surface epithelial tumors based on correlation of histologic and molecular pathologic data. Int. J. Gynecol. Pathol. 23:200-205
52. Michaloglou C, Vredeveld LC, Mooi WJ, Peeper DS. 2008. BRAF(E600) in benign and malignant human tumours. Oncogene 27:877-895 (Pubitemid 351225383)
53. Davidson B, Givant-Horwitz V, Lazarovici P, Risberg B, Nesland JM, et al. 2003. Matrix metalloproteinases (MMP), EMMPRIN (extracellular matrix metalloproteinase inducer) and mitogen-activated protein kinases (MAPK): coexpression in metastatic serous ovarian carcinoma. Clin. Exp. Metastasis 20:621-631 (Pubitemid 37463899)
54. Schraml P, Schwerdtfeger G, Burkhalter F, Raggi A, Schmidt D, et al. 2003. Combined array comparative genomic hybridization and tissue microarray analysis suggest PAK1 at 11q13.5-q14 as a critical oncogene target in ovarian carcinoma. Am. J. Pathol. 163:985-992 (Pubitemid 37040134)
55. Meinhold-Heerlein I, Bauerschlag D, Hilpert F, Dimitrov P, Sapinoso LM, et al. 2005. Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential. Oncogene 24:1053-1065 (Pubitemid 40313882)
56. Mayr D, Kanitz V, Anderegg B, Luthardt B, Engel J, et al. 2006. Analysis of gene amplification and prognostic markers in ovarian cancer using comparative genomic hybridization for microarrays and immunohistochemical analysis for tissue microarrays. Am. J. Clin. Pathol. 126:101-109 (Pubitemid 44025077)
57. Nowee ME, Snijders AM, Rockx DA, de Wit RM, Kosma VM, et al. 2007. DNA profiling of primary serous ovarian and fallopian tube carcinomas with array comparative genomic hybridization and multiplex ligation-dependent probe amplification. J. Pathol. 213:46-55
58. Arboleda MJ, Lyons JF, Kabbinavar FF, Bray MR, Snow BE, et al. 2003. Overexpression of AKT2/protein kinase Bβ leads to up-regulation of β1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells. Cancer Res. 63:196-206
59. Dan HC, Sun M, Kaneko S, Feldman RI, Nicosia SV, et al. 2004. Akt phosphorylation and stabilization of X-linked inhibitor of apoptosis protein (XIAP). J. Biol. Chem. 279:5405-5412 (Pubitemid 38220563)
60. Meng Q, Xia C, Fang J, Rojanasakul Y, Jiang BH. 2006. Role of PI3K and AKT specific isoforms in ovarian cancer cell migration, invasion and proliferation through the p70S6K1 pathway. Cell. Signal. 18:2262-2271 (Pubitemid 44636166)
61. Bortner DM, Rosenberg MP. 1997. Induction of mammary gland hyperplasia and carcinomas in transgenic mice expressing human cyclin E. Mol. Cell Biol. 17:453-459
62. Bedrosian I, Lu KH, Verschraegen C, Keyomarsi K. 2004. Cyclin E deregulation alters the biologic properties of ovarian cancer cells. Oncogene 23:2648-2657 (Pubitemid 38586318)
63. Spruck CH, Won KA, Reed SI. 1999. Deregulated cyclin E induces chromosome instability. Nature 401:297-300 (Pubitemid 129515546)
64. Minella AC, Swanger J, Bryant E, Welcker M, Hwang H, Clurman BE. 2002. p53 and p21 form an inducible barrier that protects cells against cyclin E-cdk2 deregulation. Curr. Biol. 12:1817-1827 (Pubitemid 35273901)
65. Farley J, Smith LM, Darcy KM, Sobel E, O'Connor D, et al. 2003. Cyclin E expression is a significant predictor of survival in advanced, suboptimally debulked ovarian epithelial cancers: a Gynecologic Oncology Group study. Cancer Res. 63:1235-1241 (Pubitemid 36348700)
66. Davidson B, Skrede M, Silins I, Shih IeM, Trope CG, Florenes VA. 2007. Low-molecular-weight forms of cyclin E differentiate ovarian carcinoma from cells of mesothelial origin and are associated with poor survival in ovarian carcinoma. Cancer 110:1264-1271 (Pubitemid 47435597)
67. Shih IeM, Sheu JJ, Santillan A, Nakayama K, Yen MJ, et al. 2005. Amplification of a chromatin remodeling gene, Rsf-1/HBXAP, in ovarian carcinoma. Proc. Natl. Acad. Sci. USA 102:14004-14009 (Pubitemid 41377693)
68. Park JT, Li M, Nakayama K, Mao TL, Davidson B, et al. 2006. Notch3 gene amplification in ovarian cancer. Cancer Res. 66:6312-6318
69. Okawa ER, Gotoh T, Manne J, Igarashi J, Fujita T, et al. 2008. Expression and sequence analysis of candidates for the 1p36.31 tumor suppressor gene deleted in neuroblastomas. Oncogene 27:803-810 (Pubitemid 351186313)
70. Bagchi A, Papazoglu C, Wu Y, Capurso D, Brodt M, et al. 2007. CHD5 is a tumor suppressor at human 1p36. Cell 128:459-475 (Pubitemid 46198889)
71. Bommer GT, Gerin I, Feng Y, Kaczorowski AJ, Kuick R, et al. 2007. p53-mediated activation of miRNA34 candidate tumor suppressor genes. Curr. Biol. 17:1298-1307 (Pubitemid 47176893)
72. He X, He L, Hannon GJ. 2007. The guardian's little helper: microRNAs in the p53 tumor suppressor network. Cancer Res. 67:11099-11101 (Pubitemid 350248530)
73. Hough CD, Sherman-Baust CA, Pizer ES, Montz FJ, Im DD, et al. 2000. Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer. Cancer Res. 60:6281-6287
74. Hough CD, Cho KR, Zonderman AB, Schwartz DR, Morin PJ. 2001. Coordinately up-regulated genes in ovarian cancer. Cancer Res. 61:3869-3876 (Pubitemid 32720943)
75. Bonome T, Lee JY, Park DC, Radonovich M, Pise-Masison C, et al. 2005. Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Cancer Res. 65:10602-10612 (Pubitemid 41743756)
76. Gilks CB, Vanderhyden BC, Zhu S, van de Rijn M, Longacre TA. 2005. Distinction between serous tumors of low malignant potential and serous carcinomas based on global mRNA expression profiling. Gynecol. Oncol. 96:684-694 (Pubitemid 40255487)
77. Landen CN Jr, Birrer MJ, Sood AK. 2008. Early events in the pathogenesis of epithelial ovarian cancer. J. Clin. Oncol. 26:995-1005
78. Singer G, Rebmann V, Chen YC, Liu HT, Ali SZ, et al. 2003. HLA-G is a potential tumor marker in malignant ascites. Clin. Cancer Res. 9:4460-4464 (Pubitemid 37248404)
79. Sheu JJ, Shih IeM. 2007. Clinical and biological significance of HLA-G expression in ovarian cancer. Semin. Cancer Biol. 17:436-443 (Pubitemid 350052589)
80. Vassilopoulos I, Korkolopoulou P, Konstantinidou AE, Patsouris E, Eftichiadis C, et al. 2003. Evaluation of the cyclin-dependent kinase inhibitor p21Cip1 in epithelial ovarian tumors of low malignant potential and adenocarcinomas. Histol. Histopathol. 18:761-770 (Pubitemid 36773221)
81. Cannistra SA. 2007. BRCA-1 in sporadic epithelial ovarian cancer: lessons learned from the genetics of hereditary disease. Clin. Cancer Res. 13:7225-7227
82. Wang C, Horiuchi A, Imai T, Ohira S, Itoh K, et al. 2004. Expression of BRCA1 protein in benign, borderline, and malignant epithelial ovarian neoplasms and its relationship to methylation and allelic loss of the BRCA1 gene. J. Pathol. 202:215-223 (Pubitemid 38208659)
83. Baldwin RL, Nemeth E, Tran H, Shvartsman H, Cass I, et al. 2000. BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study. Cancer Res. 60:5329-5333 (Pubitemid 30761235)
84. Press JZ, De Luca A, Boyd N, Young S, Troussard A, et al. 2008. Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer 8:17 (Pubitemid 351279967)
85. Acs G, Pasha T, Zhang PJ. 2004. WT1 is differentially expressed in serous, endometrioid, clear cell, and mucinous carcinomas of the peritoneum, fallopian tube, ovary, and endometrium. Int. J. Gynecol. Pathol. 23:110-118 (Pubitemid 38391769)
86. O'Neill CJ, Deavers MT, Malpica A, Foster H, McCluggage WG. 2005. An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas: significantly higher expression of p53, MIB1, BCL2, HER-2/neu, and C-KIT in high-grade neoplasms. Am. J. Surg. Pathol. 29:1034-1041 (Pubitemid 41045547)
87. DePriest PD, Banks ER, Powell DE, van Nagell JR Jr, Gallion HH, et al. 1992. Endometrioid carcinoma of the ovary and endometriosis: the association in postmenopausal women. Gynecol. Oncol. 47:71-75
88. Fukunaga M, Nomura K, Ishikawa E, Ushigome S. 1997. Ovarian atypical endometriosis: its close association with malignant epithelial tumours. Histopathology 30:249-255 (Pubitemid 27148154)
89. Yoshikawa H, Jimbo H, Okada S, Matsumoto K, Onda T, et al. 2000. Prevalence of endometriosis in ovarian cancer. Gynecol. Obstet. Invest. 50(Suppl.1):11-17
90. Erzen M, Rakar S, Klancnik B, Syrjanen K, Klancar B. 2001. Endometriosis-associated ovarian carcinoma (EAOC): an entity distinct from other ovarian carcinomas as suggested by a nested case-control study. Gynecol. Oncol. 83:100-108 (Pubitemid 32959885)
91. Sainz de la Cuesta R, Eichhorn JH, Rice LW, Fuller AF Jr, Nikrui N, Goff BA. 1996. Histologic transformation of benign endometriosis to early epithelial ovarian cancer. Gynecol. Oncol. 60:238-244 (Pubitemid 26058768)
92. Thomas EJ, Campbell IG. 2000. Molecular genetic defects in endometriosis. Gynecol. Obstet. Investig. 50(Suppl.1):44-50
93. Bell KA, Kurman RJ. 2000. A clinicopathologic analysis of atypical proliferative (borderline) tumors and well-differentiated endometrioid adenocarcinomas of the ovary. Am. J. Surg. Pathol. 24:1465-1479
94. Wright K, Wilson P, Morland S, Campbell I, Walsh M, et al. 1999. β-catenin mutation and expression analysis in ovarian cancer: exon 3 mutations and nuclear translocation in 16% of endometrioid tumours. Int. J. Cancer 82:625-629 (Pubitemid 29356957)
95. Sagae S, Kobayashi K, Nishioka Y, Sugimura M, Ishioka S, et al. 1999. Mutational analysis of β-catenin gene in Japanese ovarian carcinomas: frequent mutations in endometrioid carcinomas. Jpn. J. Cancer Res. 90:510-515 (Pubitemid 29267704)
96. Wu R, Zhai Y, Fearon ER, Cho KR. 2001. Diverse mechanisms of β-catenin deregulation in ovarian endometrioid adenocarcinomas. Cancer Res. 61:8247-8255 (Pubitemid 33091619)
97. Moreno-Bueno G, Gamallo C, Perez-Gallego L, de Mora JC, Suarez A, Palacios J. 2001. β-catenin expression pattern, β-catenin gene mutations, and microsatellite instability in endometrioid ovarian carcinomas and synchronous endometrial carcinomas. Diagn. Mol. Pathol. 10:116-122 (Pubitemid 32525880)
98. Gamallo C, Palacios J, Moreno G, Calvo de Mora J, Suarez A, Armas A. 1999. β-catenin expression pattern in stage I and II ovarian carcinomas: relationship with β-catenin gene mutations, clinicopathological features, and clinical outcome. Am. J. Pathol. 155:527-536 (Pubitemid 29370402)
99. Saegusa M, Okayasu I. 2001. Frequent nuclear β-catenin accumulation and associated mutations in endometrioid-type endometrial and ovarian carcinomas with squamous differentiation. J. Pathol. 194:59-67
100. Obata K, Morland SJ, Watson RH, Hitchcock A, Chenevix-Trench G, et al. 1998. Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors. Cancer Res. 58:2095-2097 (Pubitemid 28232892)
101. Catasus L, Bussaglia E, Rodrïguez I, Gallardo A, Pons C, et al. 2004. Molecular genetic alterations in endometrioid carcinomas of the ovary: similar frequency of β-catenin abnormalities but lower rate of microsatellite instability and PTEN alterations than in uterine endometrioid carcinomas. Hum. Pathol. 35:1360-1368 (Pubitemid 39601576)
102. Altomare DA, Testa JR. 2005. Perturbations of the AKT signaling pathway in human cancer. Oncogene 24:7455-7464 (Pubitemid 41637985)
103. Campbell IG, Russell SE, Choong DY, Montgomery KG, Ciavarella ML, et al. 2004. Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res. 64:7678-7681 (Pubitemid 39446895)
104. Oda K, Stokoe D, Taketani Y, McCormick F. 2005. High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Cancer Res. 65:10669-10673 (Pubitemid 41713332)
105. Catasus L, Gallardo A, Cuatrecasas M, Prat J. 2008. PIK3CA mutations in the kinase domain (exon 20) of uterine endometrial adenocarcinomas are associated with adverse prognostic parameters. Mod. Pathol. 21:131-139 (Pubitemid 351172164)
106. Enomoto T, Weghorst CM, Inoue M, Tanizawa O, Rice JM. 1991. K-ras activation occurs frequently in mucinous adenocarcinomas and rarely in other common epithelial tumors of the human ovary. Am. J. Pathol. 139:777-785
107. Caduff RF, Svoboda-Newman SM, Bartos RE, Ferguson AW, Frank TS. 1998. Comparative analysis of histologic homologues of endometrial and ovarian carcinoma. Am. J. Surg. Pathol. 22:319-326
108. Amemiya S, Sekizawa A, Otsuka J, Tachikawa T, Saito H, Okai T. 2004. Malignant transformation of endometriosis and genetic alterations of K-ras and microsatellite instability. Int. J. Gynaecol. Obstet. 86:371-376 (Pubitemid 39119945)
109. Liu J, Albarracin CT, Chang KH, Thompson-Lanza JA, Zheng W, et al. 2004. Microsatellite instability and expression of hMLH1 and hMSH2 proteins in ovarian endometrioid cancer. Mod. Pathol. 17:75-80 (Pubitemid 41656455)
110. Kolasa IK, Rembiszewska A, Janiec-Jankowska A, Dansonka-Mieszkowska A, Lewandowska AM, et al. 2006. PTEN mutation, expression and LOH at its locus in ovarian carcinomas. Relation to TP53, K-RAS and BRCA1 mutations. Gynecol. Oncol. 103:692-697 (Pubitemid 44602189)
111. Tapper J, Butzow R, Wahlstrom T, Seppala M, Knuutila S. 1997. Evidence for divergence of DNA copy number changes in serous, mucinous and endometrioid ovarian carcinomas. Br. J. Cancer 75:1782-1787 (Pubitemid 27230704)
112. Zorn KK, Bonome T, Gangi L, Chandramouli GV, Awtrey CS, et al. 2005. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Clin. Cancer Res. 11:6422-6430 (Pubitemid 41338978)
113. Sato N, Tsunoda H, Nishida M, Morishita Y, Takimoto Y, et al. 2000. Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary. Cancer Res. 60:7052-7056 (Pubitemid 32059184)
114. Fujita M, Enomoto T, Yoshino K, Nomura T, Buzard GS, et al. 1995. Microsatellite instability and alterations in the hMSH2 gene in human ovarian cancer. Int. J. Cancer 64:361-366 (Pubitemid 26048903)
115. King BL, Carcangiu ML, Carter D, Kiechle M, Pfisterer J, et al. 1995. Microsatellite instability in ovarian neoplasms. Br. J. Cancer 72:376-382
116. Mok CH, Bell DA, Knapp RC, Fishbaugh PM, Welch WR, et al. 1993. Mutation of K-ras protooncogene in human ovarian epithelial tumors of borderline malignancy. Cancer Res. 53:1489-1492 (Pubitemid 23113216)
117. Ichikawa Y, Nishida M, Suzuki H, Yoshida S, Tsunoda H, et al. 1994. Mutation of K-ras protooncogene is associated with histological subtypes in human mucinous ovarian tumors. Cancer Res. 54:33-35 (Pubitemid 24042083)
118. Gemignani ML, Schlaerth AC, Bogomolniy F, Barakat RR, Lin O, et al. 2003. Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma. Gynecol. Oncol. 90:378-381 (Pubitemid 36952030)
119. Cuatrecasas M, Villanueva A, Matias-Guiu X, Prat J. 1997. K-ras mutations in mucinous ovarian tumors: a clinicopathologic and molecular study of 95 cases. Cancer 79:1581-1586 (Pubitemid 27154791)
120. Suehiro Y, Sakamoto M, Umayahara K, Iwabuchi H, Sakamoto H, et al. 2000. Genetic aberrations detected by comparative genomic hybridization in ovarian clear cell adenocarcinomas. Oncology 59:50-56 (Pubitemid 30435836)
121. Dent J, Hall GD, Wilkinson N, Perren TJ, Richmond I, et al. 2003. Cytogenetic alterations in ovarian clear cell carcinoma detected by comparative genomic hybridisation. Br. J. Cancer 88:1578-1583 (Pubitemid 36713785)
122. Wang K, Gan L, Jeffery E, Gayle M, Gown AM, et al. 1999. Monitoring gene expression profile changes in ovarian carcinomas using cDNA microarray. Gene 229:101-108 (Pubitemid 29148312)
123. Welsh JB, Zarrinkar PP, Sapinoso LM, Kern SG, Behling CA, et al. 2001. Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. Proc. Natl. Acad. Sci. USA 98:1176-1181
124. Reed E, Yu JJ, Davies A, Gannon J, Armentrout SL. 2003. Clear cell tumors have higher mRNA levels of ERCC1 and XPB than other histological types of epithelial ovarian cancer. Clin. Cancer Res. 9:5299-5305 (Pubitemid 37413583)
125. Tsuchiya A, Sakamoto M, Yasuda J, Chuma M, Ohta T, et al. 2003. Expression profiling in ovarian clear cell carcinoma: identification of hepatocyte nuclear factor-1β as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma. Am. J. Pathol. 163:2503-2512 (Pubitemid 37466491)
126. Senkel S, Lucas B, Klein-Hitpass L, Ryffel GU. 2005. Identification of target genes of the transcription factor HNF1β and HNF1α in a human embryonic kidney cell line. Biochim. Biophys. Acta 1731:179-190 (Pubitemid 41735113)
127. Tanaka T, Tomaru Y, Nomura Y, Miura H, Suzuki M, Hayashizaki Y. 2004. Comprehensive search for HNF1β-regulated genes in mouse hepatoma cells perturbed by transcription regulatory factor-targeted RNAi. Nucleic Acids Res. 32:2740-2750 (Pubitemid 38885945)
128. Heinzelmann-Schwarz VA, Gardiner-Garden M, Henshall SM, Scurry JP, Scolyer RA, et al. 2006. A distinct molecular profile associated with mucinous epithelial ovarian cancer. Br. J. Cancer 94:904-913
129. Orsulic S, Li Y, Soslow RA, Vitale-Cross LA, Varmus HE. 2002. Induction of ovarian cancer by defined multiple genetic changes in a mouse model system. Cancer Cell 1:53-62 (Pubitemid 41039176)
130. Connolly DC, Bao R, Nikitin AY, Stephens KC, Poole TW, et al. 2003. Female mice chimeric for expression of the simian virus 40 TAg under control of the MISIIR promoter develop epithelial ovarian cancer. Cancer Res. 63:1389-1397 (Pubitemid 36348722)
131. Flesken-Nikitin A, Choi KC, Eng JP, Shmidt EN, Nikitin AY. 2003. Induction of carcinogenesis by concurrent inactivation of p53 and Rb1 in the mouse ovarian surface epithelium. Cancer Res. 63:3459-3463 (Pubitemid 36793020)
132. Dinulescu DM, Ince TA, Quade BJ, Shafer SA, Crowley D, Jacks T. 2005. Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. Nat. Med. 11:63-70 (Pubitemid 40215839)
133. Powis G, Ihle N, Kirkpatrick DL. 2006. Practicalities of drugging the phosphatidylinositol-3-kinase/Akt cell survival signaling pathway. Clin. Cancer Res. 12:2964-2966 (Pubitemid 43837339)
134. Inoki K, Ouyang H, Zhu T, Lindvall C, Wang Y, et al. 2006. TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell 126:955-968 (Pubitemid 44310775)
135. Rubio-Viqueira B, Hidalgo M. 2006. Targeting mTOR for cancer treatment. Curr. Opin. Investig. Drugs 7:501-512
136. Safran M, Kim WY, Kung AL, Horner JW, DePinho RA, Kaelin WG Jr. 2003. Mouse reporter strain for noninvasive bioluminescent imaging of cells that have undergone Cre-mediated recombination. Mol. Imaging 2:297-302
137. Shih IeM, Kurman RJ. 2004. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am. J. Pathol. 164:1511-1518
138. Shih IeM, Kurman RJ. 2005. Molecular pathogenesis of ovarian borderline tumors: new insights and old challenges. Clin. Cancer Res. 11:7273-7279
139. Lee Y, Miron A, Drapkin R, Nucci MR, Medeiros F, et al. 2007. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J. Pathol. 211:26-35 (Pubitemid 46092026)
140. Crum CP, Drapkin R, Miron A, Ince TA, Muto M, et al. 2007. The distal fallopian tube: a new model for pelvic serous carcinogenesis. Curr. Opin. Obstet. Gynecol. 19:3-9 (Pubitemid 46095865)
141. Kurman RJ, Visvanathan K, Roden R, Wu TC, Shih IeM. 2008. Early detection
142. Jacobs IJ, Skates SJ, MacDonald N, Menon U, Rosenthal AN, et al. 1999. Screening for ovarian cancer: a pilot randomised controlled trial. Lancet 353:1207-1210 (Pubitemid 29168457)
143. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. 2002. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J. Clin. Oncol. 20:1248-1259
144. Lee KW, Kang NJ, Heo YS, Rogozin EA, Pugliese A, et al. 2008. Raf and MEK protein kinases are direct molecular targets for the chemopreventive effect of quercetin, a major flavonol in red wine. Cancer Res. 68:946-955 (Pubitemid 351206774)